The Work Group kept in contact with these other organizations and sought to achieve consistency with their recommendations as much as possible. Measurement of BP The Work Group recognized that many reviews on the methodology of BP measurement have been published9,10 and that this topic was covered in detail in the 2004 KDOQI Previous publications have highlighted incon- sistencies between conventional office (or clinic) BP measure- ments and other methods, such as self-measurement of BP at home or ambulatory blood pressure monitoring (ABPM).11 13 Many recommendations regarding when and how to use ABPM in hypertensive patients not known to have CKD have also been published. Although few studies have assessed the value of ABPM CKD patients, the small, short-term studies that do exist reflect the inconsistency between office BP measurements and other BP measurements and also suggest that ABPM gives a better indication of overall BP and kidney prognosis than office BP measurements.11 13 Despite this, to date there has only been one large RCT of BP control in CKD patients (all of whom were children) in which ABPM was used as the method for BP assessment.14 We therefore cannot provide evidence-based recommendations regarding the use of ABPM to evaluate BP in CKD patients but existing evidence is reviewed in Chapter 8. Since office BP measurements are used in almost all RCTs of interventions that modify BP in CKD, this Guideline can only make recommendations about BP assessed by this method. Because office readings are known to vary from day to day, management decisions should be based on repeated as emphasized in this guideline by the use of the term consistently (e.g., Recommendation 4.1 y maintain a BP that is consistently r140 mm Hg systolic y). 